Paper8306370
7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine.
Pope BL and 4 others. Cancer Immunol Immunother, 1994. Cited by 22 papers, by iCite.
Cite this record
ConductScience Library. 7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine. Papers, record 8306370. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8306370
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- 7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Guanosine | Major topic |
| Melanoma, Experimental | Major topic |
| Adjuvants, Immunologic | |
| Animals | |
| G(M1) Ganglioside | |
| Interleukin-2 | |
| Lung Neoplasms | |
| Mice | |
| Mice, Inbred C57BL | |
| Neoplasm Metastasis | |
| Vaccines |
Source PubMed
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1914279 | Successful immunotherapy of murine melanoma metastases with 7-thia-8-oxoguanosine. | Clin Exp Metastasis | 1991 | https://conductscience.org/library/papers/1914279 | PubMed |
| 2 | 8453674 | In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine). | Cell Immunol | 1993 | https://conductscience.org/library/papers/8453674 | PubMed |
| 3 | 3263900 | Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. | Cancer Res | 1988 | https://conductscience.org/library/papers/3263900 | PubMed |
| 4 | 3584981 | Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. | J Immunol | 1987 | https://conductscience.org/library/papers/3584981 | PubMed |
| 5 | 221611 | Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice. | J Exp Med | 1979 | https://conductscience.org/library/papers/221611 | PubMed |
| 6 | 2512580 | Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. | Proc Natl Acad Sci U S A | 1989 | https://conductscience.org/library/papers/2512580 | PubMed |
| 7 | 7061177 | In vivo reduction of NK activity with anti-NK 1 serum: direct evaluation of NK cells in tumor clearance. | Int J Cancer | 1982 | https://conductscience.org/library/papers/7061177 | PubMed |
| 8 | 6176669 | Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. | J Exp Med | 1982 | https://conductscience.org/library/papers/6176669 | PubMed |
| 9 | 953987 | Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with concanavalin A. | Cancer Res | 1976 | https://conductscience.org/library/papers/953987 | PubMed |
| 10 | 1389903 | Effective in vivo induction of lymphokine-activated killer (LAK) cells by pretreatment with a streptococcal preparation, OK-432. | Biotherapy | 1992 | https://conductscience.org/library/papers/1389903 | PubMed |
| 11 | 2452203 | Activation of murine natural killer cells and macrophages by 8-bromoguanosine. | J Immunol | 1988 | https://conductscience.org/library/papers/2452203 | PubMed |
| 12 | 1693058 | Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice. | Antiviral Res | 1990 | https://conductscience.org/library/papers/1693058 | PubMed |
| 13 | 2297770 | Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model. | Cancer Res | 1990 | https://conductscience.org/library/papers/2297770 | PubMed |
| 14 | 2137327 | Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha. | Arch Surg | 1990 | https://conductscience.org/library/papers/2137327 | PubMed |
| 15 | 3262772 | Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes. | J Natl Cancer Inst | 1988 | https://conductscience.org/library/papers/3262772 | PubMed |
| 16 | 1346654 | Progress and prospects for human cancer vaccines. | J Natl Cancer Inst | 1992 | https://conductscience.org/library/papers/1346654 | PubMed |
| 17 | 1860616 | Tumor vaccines. | FASEB J | 1991 | https://conductscience.org/library/papers/1860616 | PubMed |
| 18 | 2679456 | Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. | Ann Surg | 1989 | https://conductscience.org/library/papers/2679456 | PubMed |
| 19 | 2512355 | Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. | J Immunol | 1989 | https://conductscience.org/library/papers/2512355 | PubMed |
| 20 | 1701343 | Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. | Cancer Res | 1990 | https://conductscience.org/library/papers/1701343 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 34058283 | Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. | Adv Drug Deliv Rev | 2021 | https://conductscience.org/library/papers/34058283 | PubMed |
| 32203790 | Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. | Eur J Med Chem | 2020 | https://conductscience.org/library/papers/32203790 | PubMed |
| 31835892 | Transcriptomic Analyses Revealed Systemic Alterations in Gene Expression in Circulation and Tumor Microenvironment of Colorectal Cancer Patients. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31835892 | PubMed |
| 30568763 | The emerging chemical patterns applied in predicting human toll-like receptor 8 agonists. | Medchemcomm | 2018 | https://conductscience.org/library/papers/30568763 | PubMed |
| 28620298 | Anti-tumor Activity of Toll-Like Receptor 7 Agonists. | Front Pharmacol | 2017 | https://conductscience.org/library/papers/28620298 | PubMed |
| 23151919 | Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling. | Molecules | 2012 | https://conductscience.org/library/papers/23151919 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8306370
GET https://conductscience.org/api/papers/v1/8306370/references?page=2